HP518

HP518 is an orally available androgen receptor (AR)-targeted protein degrader developed using proteolysis targeting chimera (PROTAC) technology. It is designed to degrade both wild-type AR and clinically relevant AR ligand-binding domain mutants, including those resistant to current antiandrogen therapies such as enzalutamide. HP518 has demonstrated potent antineoplastic activity in preclinical models of prostate cancer and androgen receptor–positive triple-negative breast cancer (AR+ TNBC), showing significant tumor reduction and a favorable safety profile. In clinical studies, HP518 has shown encouraging efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) and AR+ TNBC, including partial responses and durable PSA reductions. The drug is being evaluated in ongoing Phase 1/2 trials for these indications, with FDA Fast Track designation granted for the treatment of AR+ TNBC[1][2][3][4][5][6][7].